J Neurol Surg B Skull Base 2017; 78(01): 037-042
DOI: 10.1055/s-0036-1584310
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Update on Surgical Outcomes of Lateral Temporal Bone Resection for Ear and Temporal Bone Malignancies

Sumi Sinha
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
,
Matthew M. Dedmon
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
,
Matthew R. Naunheim
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
,
Jennifer C. Fuller
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
,
Stacey T. Gray
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
,
Derrick T. Lin
1   Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
› Author Affiliations
Further Information

Publication History

11 April 2016

17 April 2016

Publication Date:
10 June 2016 (online)

Preview

Abstract

Objectives Review outcomes of lateral temporal bone resections for ear and temporal bone malignancy.

Design, Setting, and Participants Retrospective review of all lateral temporal bone resections performed from 2008 to 2015 at a single tertiary care center.

Main Outcome Measures Patient demographics, perioperative variables, overall survival, disease-free survival (DFS), and comparison of Kaplan–Meier curves.

Results Overall, 56 patients were identified with a mean follow-up period of 2.3 ± 1.8 years. The predominant histopathologic diagnosis was squamous cell carcinoma (SCC, 54%), followed by salivary gland tumors (18%), and basal cell carcinoma (9%). Tumor stages were T1-T2 in 23%, T3-T4 in 73%, and two unknown primary lesions. Mean overall survival was 4.6 ± 0.4 years. Comparison of tumors with and without lymph node involvement or perineural invasion approached statistical significance for overall survival (p = 0.07 and 0.06, respectively). DFS was 2.5 ± 0.3 years. Stratification by lymph node status had a statistically significant difference in DFS (p = 0.03). Subgroup analysis of SCC patients did not reveal significant differences.

Conclusions Based on our cohort, most patients with temporal bone malignancies present with advanced disease, making it difficult to achieve negative margins. Overall, lymph node status was the strongest predictor of survival in this group.

Financial Disclosures

None.